Suppr超能文献

社区医院中患有精神分裂症谱系障碍的住院患者使用大麻的情况。

Cannabis Use in Inpatients With Schizophrenia Spectrum Disorders at a Community Hospital.

作者信息

Olayinka Olaniyi, Ojimba Chiedozie, Alemu Brook, Olaolu Olalekan, Edomias Desta, Popoola Olusegun, Kallikkadan Jisha, Tumenta Terence, Gayam Vijay, Valbrun Leon, Olupona Tolu, Hershberger Jason

机构信息

Department of Psychiatry and Behavioral Sciences, Interfaith Medical Center, Brooklyn, NY, USA.

Integrated Health Sciences Program, School of Health Sciences, Western Carolina University, Cullowhee, NC, USA.

出版信息

J Clin Med Res. 2020 Apr;12(4):243-250. doi: 10.14740/jocmr4110. Epub 2020 Mar 30.

Abstract

BACKGROUND

Cannabis is the second most used recreational drug in the United States and one of the most used substances in patients with schizophrenia spectrum disorder (SSD). Unfortunately, the increased use is likely to continue as more states legalize recreational use of cannabis. Although the association between cannabis and schizophrenia has been studied extensively, the understanding of the relationship is still evolving. In this study, we sought to determine the prevalence and potential factors associated with cannabis use (CU) among inpatients with SSD at a community teaching hospital.

METHODS

We performed a retrospective review of the electronic medical charts of patients discharged from the psychiatric unit of our hospital from July 1, 2017 through October 31, 2017. Patients were included in this study if: 1) They were ≥ 18 years old; 2) They had discharge diagnosis of SSD; and 3) They had urine drug testing performed. Pertinent sociodemographic and clinical variables, including substance use status and hospital length of stay (LOS), were abstracted. Univariate frequencies and summary statistics were performed. Odds ratios (ORs) were determined by logistic regression analysis of bivariate and multivariate analyses.

RESULTS

Three hundred sixty-five (52.2%) patients had a discharge diagnosis of SSD, and only 322 had urine toxicology result for cannabinoids and were included in analysis. Of the 322 patients, 41.5% (n = 133) screened positive for cannabinoids. Of the 133 patients, 78% were African American, 15% were Hispanic and 5% were White; 77% were male and the median age was 36 years. Bivariate analyses showed tobacco use (OR: 2.8, 95% confidence interval (CI): 1.7 - 4.6), alcohol use (OR: 3.4, 95% CI: 2.9 - 7.0), younger age (OR: 2.8, 95% CI: 1.8 - 4.5), male gender (OR: 2.9, 95% CI: 2.2 - 3.2), unemployment (OR: 3.91, 95% CI: 3.49 - 7.35), homelessness (OR: 3.18, 95% CI: 2.76 - 3.84) and LOS (OR: 3.46, 95% CI: 2.93 - 4.31) were significantly associated with CU. Result of multivariate analysis was similar to that found in bivariate analysis.

CONCLUSIONS

CU appears to be prevalent among patients with SSD. Clinicians and public health professionals are encouraged to understand the health implications of its use in patients with mental illness especially against the backdrop of current marijuana laws.

摘要

背景

大麻是美国第二常用的消遣性毒品,也是精神分裂症谱系障碍(SSD)患者中最常用的物质之一。不幸的是,随着越来越多的州将大麻消遣性使用合法化,其使用量可能会继续增加。尽管大麻与精神分裂症之间的关联已得到广泛研究,但对两者关系的理解仍在不断发展。在本研究中,我们试图确定一家社区教学医院中SSD住院患者中大麻使用(CU)的患病率及相关潜在因素。

方法

我们对2017年7月1日至2017年10月31日期间从我院精神科出院的患者的电子病历进行了回顾性研究。符合以下条件的患者纳入本研究:1)年龄≥18岁;2)出院诊断为SSD;3)进行了尿液药物检测。提取了相关的社会人口统计学和临床变量,包括物质使用状况和住院时间(LOS)。进行了单变量频率分析和汇总统计。通过二元和多变量分析的逻辑回归分析确定比值比(OR)。

结果

365名(52.2%)患者出院诊断为SSD,只有322名患者有大麻素的尿液毒理学结果并纳入分析。在这322名患者中,41.5%(n = 133)大麻素筛查呈阳性。在这133名患者中,78%为非裔美国人,15%为西班牙裔人且5%为白人;77%为男性,中位年龄为36岁。二元分析显示,烟草使用(OR:2.8,95%置信区间(CI):1.7 - 4.6)、酒精使用(OR:3.4,95% CI:2.9 - 7.0)、较年轻年龄(OR:2.8,95% CI:1.8 - 4.5)、男性(OR:2.9,95% CI:2.2 - 3.2)、失业(OR:3.91,95% CI:3.49 - 7.35)、无家可归(OR:3.18,95% CI:2.76 - 3.84)和住院时间(OR:3.46,95% CI:2.93 - 4.31)与CU显著相关。多变量分析结果与二元分析结果相似。

结论

CU在SSD患者中似乎很普遍。鼓励临床医生和公共卫生专业人员了解其在精神疾病患者中使用对健康的影响,尤其是在当前大麻法律的背景下。

相似文献

1
Cannabis Use in Inpatients With Schizophrenia Spectrum Disorders at a Community Hospital.
J Clin Med Res. 2020 Apr;12(4):243-250. doi: 10.14740/jocmr4110. Epub 2020 Mar 30.
5
Conduct Disorder-Related Hospitalization and Substance Use Disorders in American Teens.
Behav Sci (Basel). 2019 Jul 5;9(7):73. doi: 10.3390/bs9070073.
6
Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study.
JAMA Psychiatry. 2016 Apr;73(4):388-95. doi: 10.1001/jamapsychiatry.2015.3229.
7
Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital.
Psychiatry J. 2019 Jun 13;2019:8629030. doi: 10.1155/2019/8629030. eCollection 2019.
9
The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems.
Soc Psychiatry Psychiatr Epidemiol. 2005 Dec;40(12):939-46. doi: 10.1007/s00127-005-0964-4. Epub 2005 Oct 25.
10
Factors Associated with Unplanned Early Discharges from a Dual Diagnosis Inpatient Detoxification Unit in Israel.
J Dual Diagn. 2018 Jul-Sep;14(3):137-147. doi: 10.1080/15504263.2018.1461965. Epub 2018 May 29.

引用本文的文献

1
Prevalence of cannabis use in people with psychosis in KwaZulu-Natal, South Africa.
S Afr J Psychiatr. 2022 Oct 21;28:1927. doi: 10.4102/sajpsychiatry.v28i0.1927. eCollection 2022.

本文引用的文献

2
Trends in Reported Marijuana Vaping Among US Adolescents, 2017-2019.
JAMA. 2020 Feb 4;323(5):475-476. doi: 10.1001/jama.2019.20185.
3
No evidence of associations between genetic liability for schizophrenia and development of cannabis use disorder.
Psychol Med. 2021 Feb;51(3):479-484. doi: 10.1017/S0033291719003362. Epub 2019 Dec 9.
4
The Changing Legal Landscape of Cannabis Use and Its Role in Youth-onset Psychosis.
Child Adolesc Psychiatr Clin N Am. 2020 Jan;29(1):145-156. doi: 10.1016/j.chc.2019.08.016. Epub 2019 Oct 9.
5
Cannabis Use and the Risk for Psychosis and Affective Disorders.
J Dual Diagn. 2020 Jan-Mar;16(1):22-42. doi: 10.1080/15504263.2019.1674991. Epub 2019 Oct 24.
6
Cannabis use and psychosis: a review of reviews.
Eur Arch Psychiatry Clin Neurosci. 2020 Jun;270(4):403-412. doi: 10.1007/s00406-019-01068-z. Epub 2019 Sep 28.
7
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.
Lancet Psychiatry. 2019 May;6(5):427-436. doi: 10.1016/S2215-0366(19)30048-3. Epub 2019 Mar 19.
8
US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws: 1991-1992 to 2012-2013.
JAMA Psychiatry. 2017 Jun 1;74(6):579-588. doi: 10.1001/jamapsychiatry.2017.0724.
9
The Effects of Psychoeducation on Long-term Inpatients with Schizophrenia and Schizoaffective Disorder.
Kurume Med J. 2017 May 8;63(3.4):61-67. doi: 10.2739/kurumemedj.MS00011. Epub 2017 Apr 3.
10
Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys.
Lancet Psychiatry. 2016 Oct;3(10):954-964. doi: 10.1016/S2215-0366(16)30208-5. Epub 2016 Aug 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验